Compass Therapeutics Q3 EPS $(0.15) Misses $(0.13) Estimate

Benzinga · 4d ago
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.13) by 15.38 percent. This is a 87.5 percent decrease over losses of $(0.08) per share from the same period last year.